Swiss drug maker Novartis AG Wednesday reported a 29 percent decline in profit for the fourth quarter from last year, reflecting lower sales. Looking ahead, Novartis expects 2016 group net sales and core operating income to be broadly in line with the prior year, after absorbing the impact of generic competition.